- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06273046
Treatment of Fecal Incontinence and Functional Defecation Disorders Using Non-instrumental Biofeedback
Tratamiento de la Incontinencia Fecal y Los Trastornos Funcionales de la defecación Mediante Biofeedback no Instrumental
Background. Rehabilitation and re-education using instrumental anorectal biofeedback are the main treatment of anorectal functional disorders producing incontinence and outlet obstructed defecation. These treatments imply intubation of patient and several sessions of treatment leading to high consumption of resources and costs.
Hypothesis. A cognitive intervention based on original audiovisual programs developed specifically for the management of anorectal functional disorders is effective in correcting anorectal function disorders that cause fecal incontinence and evacuation disorders.
Aim. To prove in two different protocols (fecal incontinence and dyssinergic defecation) the efficacy of specifically developed non-instrumental biofeedback techniques.
Selection criteria. Patients with fecal incontinence and altered sphincter function and patients with outlet obstructed evacuation referred for biofeedback treatment.
Intervention. In separate studies (incontinence and dyssynergic defecation) patients will be randomized into biofeedback and placebo groups. One session of either biofeedback or placebo intervention will be performed at the beginning of the intervention period and patients will be instructed to performed the assigned daily treatment at home. A visit for outcome assessment will be performed at 3 months in incontinence study and at 4 weeks in the dyssinergic defecation study. In addition, in the incontinence study a phone call will be performed after 6 months of the beginning of the study to evaluate treatment outcome.
Biofeedback: patients will be taught to control anal and abdominal muscular activity by providing instructions using original video supports. Patients will be instructed to perform the same exercises daily at home in scheduled times.
Placebo: a pill of placebo containing 0.3 g glucose will be administered every day at home.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gloria Santaliestra
- Email: gloria.santaliestra@vhir.org
Study Contact Backup
- Name: Jordi Serra, MD
- Phone Number: 34 932746259
- Email: jordi.serra@vallhebron.cat
Study Locations
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Vall d'Hebron
-
Contact:
- Jordi Serra, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Incontinence studies
- Patients who have at least 4 episodes of fecal incontinence during the last 14 days.
- Patients able to follow instructions and attend study visits.
Dyssinergic defecation studies
- Patients with constipation who present less than 3 complete spontaneous bowel movements per week and/or who have Bristol 1 or Bristol 2 type stools in more than 25% of the bowel movements in the 2 weeks prior to the study
- Patients able to follow instructions and attend study visits.
Exclusion Criteria:
- Patients with organic digestive diseases such as inflammatory bowel disease, celiac disease, gastro-duodenal ulcer...
- Patients with neurological diseases (spinal cord injury, multiple sclerosis, Parkinson's disease).
- Patients with previous of active colon and/or rectal cancer.
- Patients with rectal fistula.
- Patients with rectal prolapse.
- Patients with total colectomy.
- Patients who have had any radiation to the pelvis in the last month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Three visits will be made throughout the study following the same procedure as patients in the active arm.
Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home.
A final visit will be performed at the end of the study alike the active treatment group.
|
Experimental: Biofeedback
|
Three visits will be made throughout the study.
The first visit (Day -14) will consist of an evaluation of the inclusion criteria.
A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient.
The second visit will take place 14 days later (Day 0).
During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria.
Patients who meet the criteria will be randomized 2:1 to active treatment or placebo.
Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home.
A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies).
In incontinence study a final phone call will be performed at 6 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dyssinergic defecation study: Number of bowel movements
Time Frame: 4 weeks
|
Number and type (according to Bristol scale) of bowel movements during the last 15 days of study compared to the 15 days prior to treatment start.
|
4 weeks
|
Fecal incontinence study: Number of anal leaks
Time Frame: 3 months
|
Number of involuntary leaks during the last 15 days of study compared to the 15 days prior to treatment start.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dyssinergic defecation study: sensation of outlet obstructed evacuation
Time Frame: 4 weeks
|
Frequency of the following sensations: sensation of anorectal obstruction/blockage; straining; incomplete evacuation; manual maneuvers to facilitate evacuation during the bowel movements produced during the last 15 days of study compared to the 15 days prior to treatment start using daily questionnaires.
|
4 weeks
|
Dyssinergic defecation study: Wexner scale
Time Frame: 4 weeks
|
Score rated at the end of the study compared to the score rated prior to treatment start using the Wexner scale for constipation
|
4 weeks
|
Dyssinergic defecation study: Quality of life
Time Frame: 4 weeks
|
Score rated at the end of the study compared to the score rated prior to treatment start using the patient assessment quality of life questionnaire for constipation (PACQoL)
|
4 weeks
|
Dyssinergic defecation study: anxiety and depression
Time Frame: 4 weeks
|
Score rated at the end of the study compared to the score rated prior to treatment start using the hospital anxiety-depression questionnaire (HDA)
|
4 weeks
|
Dyssinergic defecation study: defecatory maneuvers
Time Frame: 4 weeks
|
Abdominal contraction pressure and anal relaxation of the anal sphincters at the end of the study compared to pressures prior to treatment start measured by anorectal manometry
|
4 weeks
|
Incontinence study: Wexner scale
Time Frame: 3 and 6 months
|
Score rated at the end of the study compared to the score rated prior to treatment start using the Wexner scale for incontinence.
|
3 and 6 months
|
Incontinence study: Quality of life
Time Frame: 3 months
|
Score rated at the end of the study compared to the score rated prior to treatment start using the quality of life questionnaire for incontinence (FIQoL)
|
3 months
|
Incontinence study: anxiety and depression
Time Frame: 3 months
|
Score rated at the end of the study compared to the score rated prior to treatment start using the hospital anxiety-depression questionnaire (HDA)
|
3 months
|
Incontinence study: Anal sphincter function
Time Frame: 3 months
|
Resting pressure and squeeze pressure of the anal sphincters at the end of the study compared to pressures prior to treatment start measured by anorectal manometry
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jordi Serra, MD, University Hospital Vall d'Hebron
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR(AG)614/2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Incontinence
-
Batterjee Medical CollegeBenha UniversityCompleted
-
Badr UniversityCompletedFecal Incontinence in ChildrenEgypt
-
Hospital Mutua de TerrassaCompletedGas Incontinence | Soilings, Fecal
-
RDD Pharma LtdWithdrawnIdiopathic Fecal IncontinenceIsrael
-
Nantes University HospitalCompletedConstipation Aggravated | Fecal Incontinence With Fecal UrgencyFrance
-
Queen Mary University of LondonCompletedBowel Incontinence | Faecal Incontinence
-
University of AarhusUniversity of Tromso; Hvidovre University HospitalCompletedFecal Incontinence | Faecal IncontinenceDenmark
-
NICHD Pelvic Floor Disorders NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFecal Incontinence | Bowel IncontinenceUnited States
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompleted
-
Massarat ZutshiCook Group IncorporatedTerminatedFecal Incontinence | Anal IncontinenceUnited States
Clinical Trials on Biofeedback
-
Technische Universität DresdenMichael J. Fox Foundation for Parkinson's Research; University Hospital Carl...CompletedAutonomic Dysfunction | Acute Ischaemic StrokeGermany
-
Klick Inc.Completed
-
L. Eugene ArnoldNational Institute of Mental Health (NIMH); Brain Resource CenterCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Icahn School of Medicine at Mount SinaiRecruitingMajor Depressive DisorderUnited States
-
Badr UniversityCompletedFecal Incontinence in ChildrenEgypt
-
The Hong Kong Polytechnic UniversityKwong Wah HospitalCompleted
-
New York UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD); Syracuse... and other collaboratorsCompletedSpeech Sound DisorderUnited States
-
Rutgers, The State University of New JerseyArthritis FoundationCompleted
-
British Columbia Cancer AgencyUniversity of British ColumbiaSuspended
-
Emory UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedAnterior Cruciate Ligament InjuriesUnited States